Dayvigo and Finasteride Interaction: What You Need to Know

Why This Combination Comes Up

Men over 40 frequently manage two conditions at once: androgenetic alopecia or benign prostatic hyperplasia (BPH) treated with finasteride, and insomnia treated with a dual orexin receptor antagonist (DORA) like lemborexant. Prescribers and patients both want to know whether these two drugs interact. The short answer is that they do not share a dangerous pharmacokinetic interaction, but the clinical picture has a few nuances worth examining.

Finasteride (brand names Propecia at 1 mg, Proscar at 5 mg) inhibits type II 5-alpha reductase, blocking the conversion of testosterone to dihydrotestosterone (DHT) 1. Lemborexant (Dayvigo, 5 mg or 10 mg) blocks orexin receptors OX1R and OX2R to promote sleep onset and maintenance 2. Because their pharmacologic targets are entirely different, the interaction question centers on shared metabolic pathways rather than receptor-level competition. The FDA-approved prescribing information for lemborexant lists CYP3A4 as the primary clearance route, which is also the enzyme that handles finasteride, and that overlap is the pivot point of this discussion 3.

CYP3A4 Metabolism: Shared Pathway, Minimal Competition

Both drugs are CYP3A4 substrates. That fact alone does not mean they compete for the enzyme in any clinically relevant way. Lemborexant reaches peak plasma concentration (Tmax) approximately 1 to 3 hours after oral dosing, with a half-life of roughly 17 to 19 hours 2. Finasteride has a Tmax of 1 to 2 hours and a terminal half-life of 5 to 6 hours in younger men, extending to approximately 8 hours in men over 70 3.

The critical detail: finasteride does not inhibit, induce, or modulate CYP3A4 activity. In vitro metabolism studies referenced in the Proscar label confirm that finasteride does not affect the cytochrome P450 enzyme system at concentrations achieved during therapeutic use 3. The lemborexant label specifically warns against co-administration with strong CYP3A4 inhibitors (such as itraconazole or clarithromycin), which can increase lemborexant AUC by approximately 4-fold 2. Finasteride does not fall into this category. It lacks the molecular structure to act as a CYP3A4 inhibitor, so it will not raise lemborexant blood levels.

Two CYP3A4 substrates passing through the same enzyme does create a theoretical possibility of competitive inhibition. In practice, the binding affinity (Ki) of finasteride for CYP3A4 is too low relative to lemborexant to produce measurable displacement. No published case reports, post-marketing safety signals, or formal DDI studies document an interaction between these two agents.

P-glycoprotein and Transporter Considerations

Lemborexant is a substrate of P-glycoprotein (P-gp), an efflux transporter that limits drug absorption and brain penetration 4. Drugs that inhibit P-gp could theoretically increase lemborexant exposure. Finasteride has not been identified as a P-gp inhibitor or substrate in clinical pharmacology databases 3.

This means the transporter pathway carries no interaction risk. The Endocrine Society's 2017 guidelines on androgen therapy note that finasteride's drug interaction profile is remarkably clean, with only weak CYP3A4 substrate activity and no significant transporter effects 5. From a transporter perspective, co-administration is straightforward.

Pharmacodynamic Overlap: CNS and Mood Effects

The more clinically relevant concern is pharmacodynamic, not pharmacokinetic. Both drugs can independently affect mood, cognition, and sleep architecture through separate mechanisms.

Lemborexant, by blocking orexin signaling, suppresses wakefulness and may cause next-day somnolence, sleep paralysis, or hypnagogic hallucinations in a small percentage of users. In the SUNRISE-2 trial (N=949), the most common adverse event was somnolence, occurring in 10% of patients on lemborexant 10 mg versus 1% on placebo 6.

Finasteride's CNS profile is different but worth noting. Post-finasteride syndrome (PFS), though controversial and not universally accepted as a distinct entity, has been described in case series and patient registries. A 2019 systematic review found that 1.4% to 3.4% of finasteride users in randomized trials reported depressive symptoms, compared with 0.9% to 1.6% on placebo 7. The mechanism is thought to involve altered neurosteroid production, specifically reduced levels of allopregnanolone, a positive allosteric modulator of GABA-A receptors 8.

This is where clinicians should pay attention. A patient on finasteride who already experiences subtle neurosteroid-mediated mood changes may be more sensitive to the sedative and mood-altering effects of orexin blockade. No published trial has measured this overlap directly, and the incidence of clinically meaningful additive effects is likely small. The prudent approach is baseline mood assessment and follow-up at 4 to 6 weeks after initiating the combination.

Dr. Andrew Huberman has cited neurosteroid pathways in discussions of sleep and hormonal health; the Endocrine Society's clinical practice guidelines recommend screening for depressive symptoms in men starting 5-alpha reductase inhibitors 5.

Timing and Practical Dosing Guidance

Given the absence of a pharmacokinetic interaction, no dose adjustment is required for either drug when taken together. Lemborexant should be taken immediately before bedtime, with at least 7 hours of intended sleep remaining. Finasteride can be taken at any consistent time of day.

A practical consideration: taking finasteride in the morning and lemborexant at bedtime separates the two drugs' peak concentrations by 12 or more hours, further reducing any hypothetical CYP3A4 substrate competition. This staggering is not pharmacologically necessary but may provide reassurance to cautious patients.

The standard doses remain unchanged:

• Lemborexant: 5 mg at bedtime for most adults; 10 mg may be used if 5 mg is ineffective 2
• Finasteride: 1 mg daily for androgenetic alopecia; 5 mg daily for BPH 3

Patients with hepatic impairment deserve extra scrutiny. Moderate hepatic impairment increases lemborexant AUC approximately 50%, and the FDA label recommends a maximum dose of 5 mg in these patients 2. Finasteride is also hepatically cleared. While no formal interaction study has been conducted in hepatically impaired patients taking both drugs, reduced clearance of both substrates through a compromised CYP3A4 pathway is at least theoretically possible.

What the DDI Databases Say

Commercial drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not flag the lemborexant-finasteride pair as a clinically significant interaction. The National Library of Medicine's DailyMed database carries no specific warning for this combination. The Beers Criteria from the American Geriatrics Society recommend caution with DORAs in elderly patients due to fall risk but do not identify finasteride as a potentiator of that risk 9.

This clean interaction profile is consistent with finasteride's well-characterized status as a "metabolic bystander." It moves through CYP3A4 without altering the enzyme's capacity for other substrates.

When to Be More Cautious

Although the combination is generally safe, certain clinical scenarios warrant heightened monitoring:

Concurrent use of moderate CYP3A4 inhibitors. If a patient is also taking fluconazole, erythromycin, verapamil, or diltiazem, the addition of even a non-interacting co-medication adds to the total hepatic metabolic burden. The lemborexant label recommends a maximum dose of 5 mg when co-administered with weak CYP3A4 inhibitors 2.

Alcohol use. Both the lemborexant and finasteride labels note that ethanol can potentiate CNS depression. A patient who drinks regularly while on both medications should be counseled about additive sedation risk.

Older adults with polypharmacy. Men over 65 taking finasteride for BPH are often on alpha-blockers, antihypertensives, and potentially other CYP3A4 substrates. In these patients, a full medication reconciliation before starting lemborexant is advisable. The SUNRISE-1 trial specifically enrolled adults aged 65 and older (N=1,006) and confirmed lemborexant's efficacy in this population, but also demonstrated higher rates of somnolence 10.

History of depression or suicidal ideation. Given the independent mood effects of both drugs, patients with a psychiatric history should have a structured follow-up plan. The FDA's 2022 class-wide labeling update for 5-alpha reductase inhibitors added suicidal ideation as a reported adverse event 11.

The Bigger Picture: Lemborexant's True Interaction Risks

Understanding where lemborexant's real interaction dangers lie helps contextualize why finasteride is a non-issue.

Strong CYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin, ritonavir) are contraindicated with lemborexant. These drugs increase lemborexant exposure by 4-fold, creating risks for profound sedation, respiratory depression, and complex sleep behaviors 2.

Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) reduce lemborexant's efficacy by accelerating its clearance. The lemborexant label recommends against this combination 2.

Other CNS depressants (benzodiazepines, opioids, other sedative-hypnotics) produce additive pharmacodynamic effects. The combination of lemborexant with zolpidem, for example, would be far more concerning than lemborexant with finasteride.

Finasteride sits outside all three of these risk categories. It is neither a CYP3A4 modulator, a CNS depressant, nor a transporter inhibitor.

Monitoring Recommendations for the Combination

For clinicians prescribing both drugs to the same patient, a reasonable monitoring plan includes:

1. Baseline assessment: document sleep quality (Pittsburgh Sleep Quality Index or equivalent), mood (PHQ-9), and sexual function (IIEF-5 or a structured history) before starting the combination.
2. Follow-up at 4 to 6 weeks: reassess sedation severity, daytime functioning, and mood. Ask specifically about next-day drowsiness, which is the most common adverse effect of lemborexant.
3. Sexual function monitoring at 3 and 6 months: finasteride can cause erectile dysfunction (reported in 3.7% vs. 1.1% placebo in the PLESS trial, N=3,040) and decreased libido (6.4% vs. 3.4% placebo) 12. Some patients misattribute these effects to lemborexant or to the combination; documenting baseline function prevents confusion.
4. Hepatic function: if the patient has known liver disease, check hepatic transaminases before starting and at 3 months.

These steps are good clinical practice for the individual drugs. The combination itself does not require additional laboratory monitoring beyond what each drug warrants alone.

Patients should receive a 5 mg starting dose of lemborexant (per the approved label), with titration to 10 mg only if sleep maintenance remains inadequate at 4 weeks and no excess sedation is observed 2.